Epigenomics' Q1 Revenues Drop, Loss Rises

The molecular diagnostics firm reported a drop in year over year revenues, but expects its revenues to pick up as tests based on its Septin9 biomarker gain traction.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.